Vincristine (1.4 mg/m2 on day 1, followed by 1 mg on days 4 and 7) was given to eight patients with thrombotic thrombocytopenic purpura (TTP) who were refractory to plasma exchange (n=4) or plasma infusion (n=4). Italian Cooperative Group for TTP. Among all the patients treated by the Italian Cooperative Group for TTP, we retrospectively reviewed the results obtained using vincristine (VCR) in 8 TTP patients (4 men and 4 women, average age: 39.25 years, range: 23-48) who did not respond to combined apheretic and pharmacologic treatment. Vincristine is sometimes used in combination with other cancer drugs. Conclusion: Vincristine offers a reasonable option for the treatment of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Seven of eight patients (87%) achieved a complete response; one was refractory to treatment and died within a few weeks. Vincristine for thrombotic thrombocytopenic purpura Previous Article Midwife's view of reports on maternity services Next Article Screening for cystic fibrosis carriers Vincristine is used to treat leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, rhabdomyosarcoma (soft tissue tumors), neuroblastoma (cancer that forms in nerve tissue), and Wilms' tumor. Patients and methods: Patients were randomly assigned to 39 weeks … The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder. Vincristine has been used in relapsed or refractory TTP, and many studies support a potential role for vincristine in the treatment of TTP (5-18). In TTP, blood clots form in small blood vessels throughout the body. Vincristine may also be used for other purposes not listed in this medication guide. Further studies evaluating vincristine in the front-line setting and in the relapsed/refractory setting are needed to validate the role of vincristine in thrombotic thrombocytopenic purpura patients. Thrombotic thrombocytopenic purpura resistant to plasma-exchange: salvage treatment with high-dose IgG or vincristine. Porta C, Bobbio-Pallavicini E, Centurioni R, Tacconi F. Int J Artif Organs, 16 Suppl 5:201-204, 01 Dec 1993 Cited by: 3 … Purpose: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristine, topotecan, and cyclophosphamide (VAC/VTC). Vincristine (1.4 mg/m 2 on day 1, followed by 1 mg on days 4 and 7) was given to eight patients with thrombotic thrombocytopenic purpura (TTP) who were refractory to plasma exchange ( n =4) or plasma infusion ( n =4). This report describes three patients with TTP and a consistent therapeutic response occurring 5 days after vincristine … Seven of eight patients (87%) achieved a complete response; one was refractory to treatment and died within a few weeks. This is the official U.S. Customs and Border Protection (CBP) website where international travelers can apply for Trusted Traveler Programs (TTP) to expedite admittance into the United States (for pre-approved, low-risk travelers). Therefore, other therapies are often used in TTP, but there is skepticism about their value, since such treatments are often used in combination, making evaluation difficult. How the drug is used in combination with current TTP treatments – such as corticosteroids, rituximab, bortezomib, vincristine, N-acetylcysteine, and splenectomy – should be evaluated to identify which treatment combinations not only improve platelet counts, but also reduce mortality and morbidity while remaining cost effective.